bispecific antibodies

Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline
Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline
Fierce Biotech
Eli Lilly
bispecific antibodies
solid tumors
Flag link:
Affimed scraps T-cell engager program, parts company with CSO
Affimed scraps T-cell engager program, parts company with CSO
Fierce Biotech
Affimed
bispecific antibodies
T-cell engager
cancer
Flag link:
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Fierce Biotech
Merck KGaA
bispecific antibodies
f-star
drug discovery
Flag link:
Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors
Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors
Pharmaceutical Business Review
Xencor
solid tumors
bispecific antibodies
clinical trials
XmAb23104
Flag link:
Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call
Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call
Endpoints
Regeneron
REGN1979
bispecific antibodies
Flag link:
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks
Fierce Biotech
Daiichi Sankyo
immuno-oncology
Zymeworks
bispecific antibodies
Flag link:
FDA draft guidance suggests comparing bispecifics to monospecific antibodies
FDA draft guidance suggests comparing bispecifics to monospecific antibodies
BioCentury
FDA
bispecific antibodies
Flag link:
Xencor, Astellas Pharma collaborate on novel bispecific antibody program
Xencor, Astellas Pharma collaborate on novel bispecific antibody program
Pharmaceutical Business Review
Xencor
Astellas
R&D
bispecific antibodies
Flag link:
Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal
Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal
Endpoints
Xencor
XmAb14045
bispecific antibodies
acute myeloid leukemia
Flag link:
The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance
The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance
Endpoints
Genentech
Xencor
IL-15
XmAb24306
cancer
bispecific antibodies
Flag link:
In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact
In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact
Fierce Biotech
Novartis
Xencor
bispecific antibodies
Flag link:
FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
Endpoints
Macrogenics
FDA
bispecific antibodies
clinical trials
B7-H3 × CD3
Flag link:
BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics
BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics
Fierce Biotech
BeiGene
Zymeworks
bispecific antibodies
ZW25
ZW49
Flag link:
GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment
GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment
CP Wire
Roche
Go Therapeutics
drug development
bispecific antibodies
Flag link:
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
Med City News
CAR-T
bispecific antibodies
BIO 2018
ASCO 2018
Flag link:
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Endpoints
Roche
bispecific antibodies
RG7716
Novartis
Eylea
Flag link:
J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table
J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table
Endpoints
JNJ
Zymeworks
drug development
bispecific antibodies
Flag link:
Amgen, Immatics In Cancer Drug Partnership
Amgen, Immatics In Cancer Drug Partnership
Investopedia
Amgen
Immatics
bispecific antibodies
R&D
cancer
Flag link:
Incyte puts up $200M in bispecifics deal with Merus
Incyte puts up $200M in bispecifics deal with Merus
BioPharma Dive
Incyte
Merus
bispecific antibodies
Flag link:
AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro
AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro
Endpoints
AstraZeneca
bispecific antibodies
MedImmune
AbPro
cancer
Flag link:

Pages